

- **Name:** Ji Hyun Park, MD.PhD.
 - **Current Position & Affiliation:** Assistant professor,
Department of Hemato-oncology,
Konkuk University Medical Center,
Konkuk University School of Medicine
 - **Country:** Republic of Korea
-

• Educational Background:

- 2002. 3 – 2004. 2: Premedical course, College of Medicine, Ewha Woman's University, Seoul, Korea
- 2004. 3 – 2008. 2: M.D., Graduate magna cum laude, College of Medicine, Ewha Woman's University, Seoul, Korea
- 2005. 7 – 2005. 8: Clerkship as a medical student, Karolinska Institute, Sweden, World Health Organization, Switzerland, Oxford University, England, In the program of LG global challenger, sponsored by LG Inc.
- 2011. 3 – 2013.2: M.S., Graduate School, University of Ulsan College of Medicine, Seoul, Korea
- 2013.3 – 2016.2: Ph.D., Graduate school, University of Ulsan College of Medicine, Seoul, Korea

• Professional Experience:

- 2008. 3 – 2009.2: Intern, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- 2009. 3 – 2013.2: Resident, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- 2014. 3 – 2017.2: Fellowship, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- 2015. 10 – 2015.11: Visiting doctor, INSERM Unit U981, instructed by Andre Fabrice, (Institut National des Sciences et de Recherche Medicale), Institut Gustave Roussy, Villejuif, France
- 2016. 7 – 2016.10: Staff in Hospitalist Task Force Team, Devise and settle a protocol for Asan Medical Center, Write a proposal for hospitalist project under the Ministry of Health and Welfare Project, which finally accepted
- 2017.3 – 2020.2: Clinical Assistant professor, Department of Hemato-oncology, Konkuk University Medical Center, Konkuk University School of Medicine
- 2020.3 – Present: Assistant professor, Department of Hemato-oncology, Konkuk University Medical Center, Konkuk University School of Medicine

• Professional Organizations:

- Member, American Society of Clinical Oncology
- Member, European Society of Medical Oncology
- Member, Korean Society of Medical Oncology
- Member, Korean Cancer Study Group
- Member, Korean Cancer Association

• Main Scientific Publications:

1. **JH Park**, GL You, MJ Ahn, S-W Kim, MH Hong, J-Y Han, C-Y Ock, J-S Lee, IJ Oh, SY Lee, CH Kim, YJ Min, YH Choi, JS Ryu, SH Park, HK Ahn, BY Shim, KH Lee, SY Lee, J-S Kim, J Yi, SK Choi, H An, JH Kang
 Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: First report from Korean Cancer Study Group
 LU19-05, 2021 Aug; 147(8):2459-2469, J Cancer Res Clin Oncol.
2. **JH Park**, SH Chun, YG Lee, H Chang, KW Lee, HR Kim, SH Shin, HJ An, KE Lee, IG Hwang, MJ Ahn, SB Kim, B Keam
 Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group
 HN 18-12 J Cancer Res Clin Oncol. 2020 Dec; 146 (12): 3359-3369, doi: 10.1007/s00432-020-03316-5
3. **JH Park**, JH Ahn, JE Kim, C KH Jung, G Gong, HJ Lee, BH Son, SH Ahn, HH Kim, HJ Shin, DH Moon, D Kim, SB Kim
 Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859] Anticancer Res. 2020 Oct; 40 (10): 5883-5893, doi: 10.21873/anticancer.14608.
4. **JH Park**, SF Jonas, G Bataillon, C Criscitello, R Salgado, S Loi, G Viale, HJ Lee, MV Dieci, S-B Kim, A Vincent-Salomon, G Curigliano, F André, S Michiels
 Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy.
 Annals of Oncology 30: 1941-1949, 2019, doi:10.1093/annonc/mdz395
5. **JH Park**, BS Kwon, SJ Park, W Ji, S Yoon, C-M Choi, JC Lee
 Exceptional pemetrexed sensitivity can predict therapeutic benefit from subsequent chemotherapy in metastatic non-squamous non-small cell lung cancer
 J Cancer Res Clin Oncol. 2019 May 29. Epub ahead
6. **JH Park**, HJ Lee, SB Lee, JH Ahn, JE Kim, KH Jung, G. Gong, B-H Son, S-H Ahn, S-B Kim
 Intrinsic prognostic impact of tumor-infiltrating lymphocytes in systemically ntrated patients with early stage triple-negative breast cancer
 Anticancer Res, 2019 Jun;39 (6):3111-3119
7. BS Kwon, **JH Park**, S Kim, S Park, W Ji, WS Kim, JC Lee, YR Park, CM Choi
 Survival benefit of first-generation epidermal growth factor receptor-tyrosine kinase inhibitors in female with advanced lung cancer
 Tumori. 2019 Jun; 105(3):216-224
8. **JH Park**, JS Lee, H Koo, JE Kim, JH Ahn, MH Ryu, SR Park, SK Yoon, JC Lee, YS Hong, SY Kim, KP Kim, CH Yoo, JY Hong, JL Lee, KH Jung, BY Rhyoo, TW Kim
 How cancer patients perceive clinical trials (CTs) in the era of CTs: current perception and its difference between common and rare cancers

J Cancer Edu, 2019 Feb, Epub ahead of print